Amylyx PharmaceuticalsAMLX
About: Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
Employees: 123
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
60% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 20
34% more capital invested
Capital invested by funds: $141M [Q3] → $189M (+$47.5M) [Q4]
9% more funds holding
Funds holding: 109 [Q3] → 119 (+10) [Q4]
8.83% more ownership
Funds ownership: 63.97% [Q3] → 72.8% (+8.83%) [Q4]
11% less repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 38
30% less call options, than puts
Call options by funds: $1.36M | Put options by funds: $1.94M
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Andrew Fein 32% 1-year accuracy 113 / 351 met price target | 227%upside $12 | Buy Reiterated | 5 Mar 2025 |
Financial journalist opinion
Based on 12 articles about AMLX published over the past 30 days









